• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Fostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial prnewswire
    June 30, 2021
    Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health ACTIV-4 trial in hospitalized patients with COVID-19.
  • NIH launches last trial of anticoagulant treatments for Covid-19 pharmaceutical-technology
    March 10, 2021
    The US National Institutes of Health (NIH) has initiated the last of three Phase III clinical trials of blood thinners (anticoagulant) to prevent life-threatening blood clots in adults with Covid-19.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service